Boston Scientific announced the close of its acquisition of Relievant Medsystems. The acquisition includes an upfront cash payment of $850M and undisclosed additional contingent payments based on sales performance over the next three years. On an adjusted basis, the transaction is expected to be immaterial to adjusted earnings per share in 2024, slightly accretive in 2025 and increasingly accretive thereafter. On a GAAP basis, the transaction is expected to be more dilutive due to amortization expense and acquisition-related charges.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BSX:
- Boston Scientific Closes Acquisition of Relievant Medsystems, Inc.
- Early notable gainers among liquid option names on November 13th
- Boston Scientific put volume heavy and directionally bearish
- Boston Scientific price target lowered to $60 from $64 at Canaccord
- BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2023